Physician profile
Matthew E Gibson
NPI 1366881187
$1,407.08
in general payments reported to CMS, 2019-2025
14 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $115 · 2022: $358 · 2023: $270 · 2024: $272 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $590.85 | 2019-2025 | |
| Sanofi Pasteur INC. | $210.37 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $195.11 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $117.09 | 2019-2022 | |
| Tris Pharma INC | $77.06 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.04 | 2019 | |
| Adlon Therapeutics L.P. | $30.25 | 2019-2020 | |
| Glaxosmithkline, LLC. | $29.61 | 2019 | |
| Neurelis, INC. | $29.38 | 2022 | |
| Corium, LLC | $21.83 | 2022 | |
| Sobi, INC | $20.11 | 2019 | |
| Abbvie INC. | $19.19 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $13.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.